NCT02872298View on ClinicalTrials.gov

Evaluating the Safety and Feasibility of TLD for the Treatment of Severe Asthma

NATerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 22, 2017

Primary Completion Date

April 6, 2020

Study Completion Date

April 6, 2020

Conditions
Asthma
Interventions
DEVICE

Targeted Lung Denervation (TLD)

The Nuvaira Lung Denervation System, manufactured by Nuvaira, Inc., is intended to deliver TLD Therapy using predetermined radiofrequency (RF) energy over a predetermined period of time to ablate airway nerve trunks which are located on the outside of the main bronchi.

Trial Locations (9)

Unknown

CHU de Grenoble, Grenoble

Thoraxklinik Heidelberg, Heidelberg

Academic Medical Center, Amsterdam

Universtity Medical Center Groningen, Groningen

Queen Elizabeth University Hospital, Glasgow

Chelsea & Westminster Hospital NHS Foundation Trust, London

Royal Brompton & Harefield NHS Foundation Trust, London

NUH Nottingham City Hospital, Nottingham

University Hospital Southampton NHS Foundation Trust, Southampton

Sponsors

Lead Sponsor

Nuvaira, Inc.
All Listed Sponsors
lead

Nuvaira, Inc.

INDUSTRY

NCT02872298 - Evaluating the Safety and Feasibility of TLD for the Treatment of Severe Asthma | Biotech Hunter | Biotech Hunter